Default company panoramic image
E7e26953 6974 4a02 8027 a8a6e5361182

ScarX Therapeutics

ScarX is developing the world's first prescription drug to reduce skin scarring; targeting a market size of over US$10 billion worldwide.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Toronto, ON, Canada
  • Currency USD
  • Founded October 2012
  • Employees 2
  • Website

Company Summary

ScarX Therapeutics is a biotech company developing a novel anti-fibrosis drug as the first prescription medication for skin scarring following surgical wound closure. In the US alone there are over 45 million surgical procedures every year that could benefit from a therapeutic to reduce skin scarring; representing a market size of over US$4 billion. ScarX is currently seeking $2.5M investment to complete a Phase I/II human clinical trial.


  • Default avatar
    Ivan Waissbluth

    Mr. Waissbluth has extensive early stage drug development and commercialization experience. Before joining ScarX Therapeutics, Ivan worked at MaRS Innovation, where he managed the development of multiple nonclinical therapeutic programs ranging from drug discovery, formulation development, and nonclinical proof of concept studies targeting a variety of different indications. Ivan also has experience performing investment diligence while working a

  • Default avatar
    Stephen Whitehead

    Stephen Whitehead is a senior executive leader in the biopharma / pharma industry with extensive experience at several leading multi-nationals. Stephen was Vice President of Commercial & Strategic Advancement, and a Management Committee Member at Wyeth. He has also held positions of increasing responsibility at American Cyanamid and J&J. Stephen has a strong background in business development, strategic planning, licensing, late-stage commerciali


  • Default avatar
    Tory's LLP